Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Clal Biotech ( (IL:CBI) ) has issued an update.
Mediwound, under Clal Biotechnology Industries Ltd., announced the approval of a Phase 3 clinical trial for its EscharEx treatment, showing a significant improvement in healing time for chronic wounds. The trial demonstrated a 14% improvement over existing treatments and a 40-day reduction in wound closure time, positioning EscharEx as a potential new standard in chronic wound care.
More about Clal Biotech
Mediwound, a leader in innovative treatment technologies, focuses on the development and commercialization of products for wound care. The company offers products such as NexoBrid for severe burns and EscharEx for chronic wounds, and is dedicated to improving patient outcomes through innovative solutions.
YTD Price Performance: -4.18%
Average Trading Volume: 113,830
Current Market Cap: ILS54.74M
Find detailed analytics on CBI stock on TipRanks’ Stock Analysis page.